

Sylvie Fauconnet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6052194/publications.pdf>

Version: 2024-02-01

14
papers

484
citations

840776

11
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

751
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure. <i>Molecular and Cellular Biochemistry</i> , 2020, 471, 113-127.	3.1	11
2	Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up. <i>BMC Cancer</i> , 2018, 18, 1239.	2.6	16
3	Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells. <i>Oncotarget</i> , 2017, 8, 107744-107762.	1.8	13
4	Apoptotic effect of the selective PPAR α agonist GW501516 in invasive bladder cancer cells. <i>Tumor Biology</i> , 2016, 37, 14789-14802.	1.8	9
5	The PPAR α agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism. <i>Cellular Signalling</i> , 2014, 26, 433-443.	3.6	6
6	The Antidiabetic Drug Ciglitazone Induces High Grade Bladder Cancer Cells Apoptosis through the Up-Regulation of TRAIL. <i>PLoS ONE</i> , 2011, 6, e28354.	2.5	27
7	Insights on distinct pathways of thiazolidinediones (PPAR γ ligand) promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells. <i>International Journal of Cancer</i> , 2010, 127, 1769-1784.	5.1	19
8	Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer. <i>Oncology Reports</i> , 2009, 21, 1495-504.	2.6	29
9	A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. <i>International Journal of Cancer</i> , 2009, 124, 1820-1828.	5.1	56
10	The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism. <i>Experimental Cell Research</i> , 2007, 313, 3239-3250.	2.6	32
11	Expression of E-Cadherin and β -, γ -Catenins in Patients With Bladder Cancer. <i>American Journal of Clinical Pathology</i> , 2006, 125, 119-126.	0.7	54
12	N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 2780-2787.	7.0	96
13	Differential Regulation of Vascular Endothelial Growth Factor Expression by Peroxisome Proliferator-activated Receptors in Bladder Cancer Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 23534-23543.	3.4	99
14	Protein kinase C signalling pathway is involved in the regulation of vascular endothelial growth factor expression in human bladder transitional carcinoma cells. <i>Cellular Signalling</i> , 2001, 13, 585-591.	3.6	17